Heat Shock Protein As Molecular Targets for Breast Cancer Therapeutics

Overview

Journal J Breast Cancer

Date 2011 Oct 28

PMID 22031796

Citations 19

Authors

Lee Su Kim

Jun Ho Kim

Affiliations

Soon will be listed here.

Abstract

Recent advances in the understanding of the molecular mechanisms involved in the breast cancer development and progression have led to the identification of numerous novel molecular targets. Among these, heat shock proteins (HSPs) are being emerging molecular target due to its diverse function in cancer cells. HSPs are highly conserved molecular chaperone that are synthesized by cell in response to various stress conditions. Mammalian HSPs have been classified into several families according to their molecular weight: HSP100, HSP90, HSP72, and small molecular HSPs (including HSP27). They are essential proteins that play a key role in cell survival through the cytoprotective mechanisms. In addition, HSPs are often overexpressed in a rage of cancers including breast cancer, and its overexpression seems to be associated with poor clinical outcomes. Also, HSP90 play a role in facilitating transformation by stabilizing the mutated and overexpressed oncoproteins found in breast cancer cell. Pharmacological targeting of HSP is therefore indicated and in the case of HSP90, numerous inhibitory drugs are undergoing clinical trial for treatment of breast cancer and other cancers. In this review, we describe the roles of HSPs in cancer cell and introduce the HSPs inhibitor as molecular target in cancer therapy and its recent clinical trials in breast cancer.

Citing Articles

Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.

Jayathirtha M, Neagu A, Whitham D, Alwine S, Darie C Am J Cancer Res. 2022; 12(4):1784-1823.

PMID: 35530281 PMC: 9077082.

Is there a role for HSF1 in viral infections?.

Reyes A, Navarro A, Diethelm-Varela B, Kalergis A, Gonzalez P FEBS Open Bio. 2022; 12(6):1112-1124.

PMID: 35485710 PMC: 9157408. DOI: 10.1002/2211-5463.13419.

Aryl Hydrocarbon Receptor Activation Produces Heat Shock Protein 90 and 70 Overexpression, Prostaglandin E2/Wnt/β-Catenin Signaling Disruption, and Cell Proliferation in MCF-7 and MDA-MB-231 Cells after 24 h and 14 Days of Chlorpyrifos Treatment.

Moyano P, Garcia J, Garcia J, Pelayo A, Munoz-Calero P, Frejo M Chem Res Toxicol. 2021; 34(9):2019-2023.

PMID: 34424684 PMC: 9132385. DOI: 10.1021/acs.chemrestox.1c00258.

Demethoxycurcumin induces apoptosis in HER2 overexpressing bladder cancer cells through degradation of HER2 and inhibiting the PI3K/Akt pathway.

Kao C, Cheng Y, Yang M, Cha T, Sun G, Ho C Environ Toxicol. 2021; 36(11):2186-2195.

PMID: 34291863 PMC: 9292507. DOI: 10.1002/tox.23332.

Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights.

Anwar M, Shalaby M, Embaby A, Saeed H, Agwa M, Hussein A Sci Rep. 2020; 10(1):14706.

PMID: 32895397 PMC: 7477571. DOI: 10.1038/s41598-020-71157-w.

References

Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K . SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res. 2008; 14(1):240-8. PMC: 3203688. DOI: 10.1158/1078-0432.CCR-07-1667. View

Garnier C, Lafitte D, Tsvetkov P, Barbier P, Millot J, Briand C . Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J Biol Chem. 2002; 277(14):12208-14. DOI: 10.1074/jbc.M111874200. View

Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis C . Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. 2009; 29(3):325-34. PMC: 3057066. DOI: 10.1038/onc.2009.337. View

Mosser D, Morimoto R . Molecular chaperones and the stress of oncogenesis. Oncogene. 2004; 23(16):2907-18. DOI: 10.1038/sj.onc.1207529. View

He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y . Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem. 2006; 49(1):381-90. DOI: 10.1021/jm0508078. View

Schaffitzel E, Rudiger S, Bukau B, Deuerling E . Functional dissection of trigger factor and DnaK: interactions with nascent polypeptides and thermally denatured proteins. Biol Chem. 2001; 382(8):1235-43. DOI: 10.1515/BC.2001.154. View

Ciocca D, Oesterreich S, Chamness G, McGuire W, Fuqua S . Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst. 1993; 85(19):1558-70. DOI: 10.1093/jnci/85.19.1558. View

Jameel A, Skilton R, Campbell T, Chander S, Coombes R, Luqmani Y . Clinical and biological significance of HSP89 alpha in human breast cancer. Int J Cancer. 1992; 50(3):409-15. DOI: 10.1002/ijc.2910500315. View

Myung J, Afjehi-Sadat L, Felizardo-Cabatic M, Slavc I, Lubec G . Expressional patterns of chaperones in ten human tumor cell lines. Proteome Sci. 2004; 2(1):8. PMC: 543454. DOI: 10.1186/1477-5956-2-8. View

10.

Ritossa F . Discovery of the heat shock response. Cell Stress Chaperones. 1996; 1(2):97-8. PMC: 248460. DOI: 10.1379/1466-1268(1996)001<0097:dothsr>2.3.co;2. View

11.

Hanson B, Vesole D . Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent. Expert Opin Investig Drugs. 2009; 18(9):1375-83. DOI: 10.1517/13543780903158934. View

12.

Whitesell L, Lindquist S . HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005; 5(10):761-72. DOI: 10.1038/nrc1716. View

13.

Pratt W, Toft D . Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003; 228(2):111-33. DOI: 10.1177/153537020322800201. View

14.

Supko J, HICKMAN R, Grever M, Malspeis L . Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995; 36(4):305-15. DOI: 10.1007/BF00689048. View

15.

Powers M, Workman P . Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 2007; 581(19):3758-69. DOI: 10.1016/j.febslet.2007.05.040. View

16.

Powers M, Clarke P, Workman P . Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell. 2008; 14(3):250-62. DOI: 10.1016/j.ccr.2008.08.002. View

17.

Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N . HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 2011; 17(15):5132-9. DOI: 10.1158/1078-0432.CCR-11-0072. View

18.

Jaattela M . Heat shock proteins as cellular lifeguards. Ann Med. 1999; 31(4):261-71. DOI: 10.3109/07853899908995889. View

19.

Prodromou C, Roe S, OBrien R, Ladbury J, Piper P, Pearl L . Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 1997; 90(1):65-75. DOI: 10.1016/s0092-8674(00)80314-1. View

20.

Kang S, Kang K, Kim K, Kwon B, Kim S, Lee H . Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer. 2008; 8:286. PMC: 2567332. DOI: 10.1186/1471-2407-8-286. View